Dividends & Buybacks ·
On August 26, 2026, shareholders of NeuroSense Therapeutics Ltd. approved a board authorization to effect one or more…
NRSNNeuroSense Therapeutics Ltd.
On August 26, 2026, shareholders of NeuroSense Therapeutics Ltd. approved a board authorization to effect one or more reverse share splits at an aggregate ratio ranging from 1-for-4 to 1-for-40. The exact ratio and effective date will be determined by the Board within 12 months. No amendment to the Articles of Association is required for this action. This company operates in the biotechnology industry, focusing on drug discovery.